Notch signaling in glioblastoma: a developmental drug target?

Maria Maddalena Lino, Adrian Merlo*, Jean-Louis Boulay

Abstract
Malignant gliomas are among the most devastating tumors for which conventional therapies have not significantly improved patient outcome. Despite advances in imaging, surgery, chemotherapy and radiotherapy, survival is still less than 2 years from diagnosis and more targeted therapies are urgently needed. Notch signaling is central to the normal and neoplastic development of the central nervous system, playing important roles in proliferation, differentiation, apoptosis and cancer stem cell regulation. Notch is also involved in the regulation response to hypoxia and angiogenesis, which are typical tumor and more specifically glioblastoma multiforme (GBM) features. Targeting Notch signaling is therefore a promising strategy for developing future therapies for the treatment of GBM. In this review we give an overview of the mechanisms of Notch signaling, its networking pathways in gliomas, and discuss its potential for designing novel therapeutic approaches.

Introduction
Gliomas are defined as brain tumors of glial origin. Based on histology, gliomas have been classified into astrocytoma (70%), oligodendroglioma (10% to 30%), mixed oligoastrocytoma and ependymoma (<10%). Low-grade gliomas, mostly astrocytomas (World Health Organization (WHO) grade II) are progressively transforming into malignant gliomas, that is, anaplastic tumors (WHO grade III) and ultimately into glioblastoma multiforme (GBM; WHO grade IV). However, most GBM are diagnosed without any prior record of a tumor of lower grade [1,2]. GBM is a complex mixture of cell types that includes astrocyte-like and stem-like cells, characterized by rapid growth and diffuse invasiveness into adjacent brain parenchyma. Resectability depends on tumor location and only the nodular component can be surgically controlled. The infiltrative component of the tumor, however, is left to unspecific and cytotoxic chemotherapy and radiotherapy that can impede tumor progression for a limited time only. GBM patient survival is of less than 1 year [2,3]. GBM has a severe mutator phenotype that consists of large chromosomal alterations [4,5]. At the genetic level, the most frequent mutations affect genes involved in the control of cell cycle, growth, apoptosis, invasion and neovascularization [6,7]. In the past few years, it has become apparent that Notch signaling, a major player in normal development of the central nervous system, is often misregulated in GBM. In this review we will focus on the role of Notch in gliomagenesis and discuss potential therapeutic opportunities.

Notch: genetics, biology and signaling
Pioneer observations on Notch in Drosophila
The Notch mutation was discovered by Thomas Morgan in 1917 in the fruit fly Drosophila melanogaster, with an adult phenotype consisting of 'notches' at the wing margin. Genetic analyses of Notch loss-of-function mutations also revealed an embryonic phenotype with an expanded population of neuroblasts at the expense of epidermis cells. These mutations provided the first clue that during neurogenesis, wild-type Notch regulates the cell fate decision by preventing ectoderm cells from differentiating into neuroblasts rather than into epidermis, and have been therefore qualified as neurogenic mutations [8]. Further identification of antineurogenic gain-of-function mutations completed the description of the allelic series of Notch [9,10]. Both loss-of-function and gain-of-function Notch mutations are dominant in Drosophila, where loss and gain of a single gene copy is sufficient to mimic hypomorphic and hypermorphic...
mutations [9-11]. Thus, the Notch expression level is likely to be critical to ensure the subtle balance between neuroblast and epidermal cell fate decision during Drosophila development.

Cloning of Notch genes
Cloning of the Drosophila Notch gene [12] revealed a type I transmembrane receptor consisting of 36 epidermal growth factor (EGF)-like tandem repeats and 3 cysteine-rich LIN-12/Notch (LIN) repeats in the extracellular domain. The extracytoplasmic juxtamembrane region forms both N-terminal and C-terminal heterodimerization domains (HD-N and HD-C, respectively). The cytoplasmic part contains an RBPJk-binding (RAM) domain, six tandem ankyrin (ANK) repeats, a transcription activation domain (TAD) and a proline/glutamate/serine/threonine-rich (PEST) sequence. Post-translational cleavage of the single Notch receptor chain at site S1 located between HD-N and HD-C domains and subsequent heterodimerization between HD-N and HD-C generates a functional receptor [13,14]. Notch1 ligands, receptor domains and processing are illustrated in Figure 1. Vertebrate genomes encode four Notch paralogs, where Notch1 and Notch2 show strong structural homology with Drosophila Notch. Notch3 and Notch4 are more distantly related, with 34 and 29 EGF-like repeats, are and devoid of TAD domains [15-18].

Expression pattern in mammalian brain
In rodent late embryonic and postnatal brain, Notch1, Notch2 and Notch3 transcripts are commonly present in germinal zones, but with distinct patterns and later postembryonic expression of Notch2 [19,20]. In postnatal mouse brain, Notch2 expression persists in glial cells harboring markers of immature phenotype: high vimentin and low glial fibrillary acidic protein (GFAP) [21]. Consistent with expression in immature glial cells in the germinal zones, Notch signaling is required for preventing neuronal differentiation and promoting neural stem cell (NSC) maintenance for further commitment into glial lineage. Maintenance of the NSC population by Notch signaling prefigures a possible role of Notch signaling in the maintenance of glioma stem cell (GSC) population [22-26].

Notch signaling mediators
In mammals, Notch receptors are activated by five type I transmembrane ligands, three Delta-like (Dll1, Dll3 and Dll4) and two Serrate/Jagged (Jag1 and Jag2) receptors (Figure 1). All contain a cysteine-rich ‘Delta, Serrate, Lag’ (DSL) motif found in Drosophila respective orthologs Delta and Serrate/Jagged and in Caenorhabditis elegans Lag2. Numbers of EGF repeats vary between Dll and Jag ligands (6-8 and 15-16, respectively) [27] Recently, epidermal growth factor-like domain 7 (EGFL7) has been identified as a soluble antagonist of Notch signaling [28]. Ligand-dependent cleavage at site S3 within the transmembrane domain (Figure 1) of the membrane-bound receptor releases a Notch intracellular (N-IC) form, which translocates to the nucleus. There, it binds Su(H)/CSL/CFB1/RBPJk to trans-activate target genes such as the hairy/enhancer of Split HES and HEY families of basic helix-loop-helix transcription factors [27,29,30]. These successive events are dissected in the upper part of Figure 2. An additional ligand-dependent cleavage at extracellular site S2 (Figure 1) leads to the release of a soluble form of Notch named Notch extracellular truncation (NEXT) [31].

Figure 1 Ligands, structure and processing of Notch1 receptor
Left: the Delta-like ligand (Dll) and Serrate-Jagged ligand (Jag) structural subsets of Notch ligands. Right: structure of Notch1 receptor resulting from post-translational cleavage at site S1 and heterodimerization of the cleaved parts. Ligand-dependent cleavages at sites S2 and S3 generate soluble Notch extracellular truncation (NEXT) and cytosolic Notch intracellular domain (N-IC) forms, respectively. Notch1 and Notch2 are highly similar. Notch3 and Notch4 contain 34 and 29 epidermal growth factor (EGF)-like repeats, and are devoid of trans-activation domain (TAD) domains.
Further, a non-canonical RBPJk-independent and Deltex-dependent alternative pathway has been described in humans and in Drosophila [32,33]. Together with this observation, in T helper (Th) cells, jagged induces Th2 cell differentiation by triggering the RBPJk-dependent canonical pathway, while Delta-like instructs Th1 commitment through a RBPJk-independent alternative pathway, presumably Deltex-dependent [34].

Physical interactions between Notch target gene products HES1 and HEY1 with Stat3 point to crosstalks between Notch and Stat3-activating pathways such as Gp130/Jak2/stat3 and Sonic hedgehog (Shh) [25,35,36]. In parallel, Shh is also capable of stimulating HES1 transcription [37]. In addition, β-catenin has been shown to interact with Notch and RBPJk to induce HES1 transcription, indicating also crosstalk between Wnt and Notch pathways [26]. Levels of crosstalks between Notch and these pathways are discussed in Hansson et al. [38].

**Notch germline mutations, human diseases and knockout models**

In humans, Notch mutations have been associated with dominant developmental disorders and diseases that include brain/neurological, cardiovascular and/or kidney defects. Notch1 in aortic valve disease [39]; Notch2 in Alagille syndrome [40]; Notch3 in Cadasil syndrome [41] and possibly Notch4 in schizophrenia [42]. In mice, global Knockouts of Notch1 or Notch2 are embryonic and perinatal lethals with vascular and kidney defects [43,44]. Surprisingly, Notch3 and Notch4 null mice showed normal development, viability and fertility. Although Notch1/Notch4 double mutants had more severe defects in angiogenic vascular remodeling, there is no evidence of a genetic interaction between Notch1 and Notch3 [45,46]. Hemizygosity of Dll4 as well as Jag1 and Rbpjk Knockouts consistently result in embryonic death due to vascular defects [47].

In fact, occurrence of disorders with embryonic or perinatal lethality are likely to mask the involvement of Notch signaling in later developmental or biological events. This includes GBM progression, onset of which occurs in human adults at the mean age of 62 [2]. Nevertheless, the fact that inactivation of Notch signaling results in constant defects in angiogenesis shows its role in vascular morphogenesis and remodeling during embryonic development, and reveals a possible involvement of Notch signaling in tumor neovasculature.

**Notch and cancer**

Notch signaling plays a pivotal role in the regulation of many fundamental cellular processes such as proliferation, stem cell maintenance, differentiation during embryonic and adult development and homeostasis of adult self-renewing organs [27,48]. Therefore, it is easy to see how perturbation of Notch signaling may often lead to tumorigenesis.

**Notch and malignancy**

The first evidence for a role of Notch in tumorigenesis came from the finding that the acute T cell lymphoblastic leukemia translocation (T-ALL) t(7;9)(q34;q34.3) breakpoint generated the fusion of the gene for the β chain of the T cell receptor at 7q34 and the TAN1/NOTCH1 gene at 9q34.3, giving rise to a constitutively active N-IC-like domain [49]. More generally, acquired gain-of-function Notch mutations in T-ALL cluster at HD domains to form constitutively active receptors, and
at the PEST domain to stabilize active N-IC [50]. Similarly, a fraction of B cell lymphomas harbor mutations in the PEST domain of Notch2 [51]. Further, Notch proteins have been shown to be involved in tumors of various origins. However, oncogenic or tumor suppressive activities of Notch depends on the cellular context [52] or might be a matter of Notch expression level, as observed in neural stem cells [53]. In other neoplasms, such as non-small cell lung cancer and skin cancer, Notch has a tumor suppressor function [6,7].

As discussed in the next section, Notch signaling is one of the major pathways involved in GBM development. Notch signaling has been shown to maintain proliferation of normal neural precursors and has been defined as a survival marker in gliomas [23-25,54]. Its oncogenic function in gliomas is based on cell proliferation and invasion [55,56]. Data on other tumor cell types showing the role of Notch in epithelial-to-mesenchymal transition (EMT) in response to hypoxia may be extrapolated to GBM [57,58].

Notch and GBM
GBM is the most aggressive central nervous system (CNS) tumor, with the poorest clinical prognosis. This tumor consists of cells that are astrocyte-like but with a complex genetic make-up and expression patterns in which the presence of stem-like cells has been proven [23,59]. Notch2 has been suggested to drive embryonic brain tumor growth, whereas Notch3 has been implicated in choroid plexus tumors [23,60]. In GBM and in medulloblastoma, the frequency and the intensity of Notch2 expression is higher than that of Notch1 [55,61]. As a consequence of local genomic amplifications at the Notch2 locus in both brain tumor types, this may also be linked to the later persistence of Notch2 expression in postnatal mouse brain [21]. In fact, in medulloblastoma, Notch2 is preferentially expressed in proliferating progenitors, while Notch1 in postmitotic differentiated cells [61]. Interestingly, Purow et al. showed that Notch1 regulates transcription of the epidermal growth factor receptor gene EGFR, known to be overexpressed or amplified in GBM, through TP53 [62]. Consistently, transcription of Notch signaling mediator genes are significantly overexpressed in the molecular subset of GBM with EGFR amplification [63]. This new link places Notch signaling as an activator of the major GBM pathway and further clarifies the implication of Notch signaling in cancer and development.

In contrast, a minor GBM subset with local haploidy at 1p12 has been identified and has been associated with better patient prognosis. Reminiscent of the better outcome of oligodendroglioma patients harboring 1p/19q loss, the minimal area of loss in GBM and the detection of homozygous deletions in oligodendroglioma converge to the Notch2 gene [54]. This provided an initial clue that subsets of gliomas (even with distinct histologies) with impaired Notch signaling result in slower progression. A single loss-of-function mutation in the RAM domain of Notch2 has been identified in the glioma line Hs683. This mutation has been further shown to impair Notch-mediated trans-activation, and subsequently tenascin-C (TNC)-mediated invasion, as detailed below [55].

Effect on proliferation and apoptosis by Notch modulation in GBM
Genomic amplification of EGFR is the most frequent genetic alteration occurring in GBM, a fraction of which undergoes a further deletion that generates the constitutively active vIII variant [64,65]. Consistently, EGF is the major proliferation pathway in GBM, mediated by activation of the RAS-RAF-MEK-ERK and the PI3K-AKT-mTOR cascades [66]. Interestingly, mTOR has recently been shown to activate Notch signaling in lung and kidney tumor cells through induction of the Stat3/p63/Jagged signaling cascade [67]. If true in GBM, this potentially creates a positive feedback loop between Notch and EGF signaling. The most frequent GBM subset consists of the association of EGFR amplification together with homozygous deletions at the CDKN2A (cyclin dependent kinase) locus, and mutually exclusive of TP53 mutations [5]. Since Notch has been shown to activate expression of EGFR via TP53 [62], Notch is expected to stimulate the main GBM proliferation pathway. Of note, the gene for the EGFR-related ERBB2 is also trans-activated by Notch, but in a DTX1-dependent manner [68].

Notch pathway inhibition by γ-secretase inhibitors (GSIs) reduced GSC proliferation and increased apoptosis associated with decreased AKT and Stat3 phosphorylation [69]. Conversely, expression of an active form of Notch2 increased tumor growth and in vivo delivery of GSI consistently blocked tumor growth, and significantly prolonged survival [69]. Taken together, these results open inhibition of Notch signaling as a promising strategy to control GSC growth.

EMT and invasion
EMT represents the transition through which a benign tumor becomes malignant. Underlying molecular changes lead to decreased cell adhesion and acquisition of tumor invasiveness [70]. Together with transforming growth factor (TGF)β, the Jag1-Notch pathway activates HEY1 to trigger EMT of epithelial cells of human, murine and canine origins [71]. The Jag1-Notch-Sna2 cascade has also been showed to induce EMT in human breast tumor cell [57]. Unlike these tumors in which invasion results into remote metastases, GBM invade
adjacent brain tissue. Further studies may validate the same molecular mechanism in GBM local invasion.

TNC, highly expressed in invasive GBM, is an extracellular matrix glycoprotein [72] that induces proliferation and migration of neuronal precursors in embryonic and postnatal mouse brain neurogenic zones [73], and ensures neuronal regeneration in injured adult brain [74]. TNC levels increase during progression of GBM, such that it can be used as a prognostic marker for GBM patient survival [75]. The molecular mechanism through which Notch signaling induces TNC-dependant glioma cell motility is based on the trans-activation of the TNC promoter by Notch-RBPJk [55]. It is noteworthy that a parallel study in childhood ependymomas has shown an association between tumor recurrence and frequent amplification of the 9qter, precisely at the location of both NOTCH1 and TNC genes [76].

Glioma differentiation and stem cells

In recent years, it had been suggested that within a tumor, only a subset of cells called cancer stem cells (CSCs), are endowed with tumorigenic capacity [77-79]. These cells are self-renewing and multipotent with tumor initiating potential. The alternative hypothesis that transformation and dedifferentiation of more mature brain cells contributes to tumorigenesis may be a parallel pathway towards tumorigenesis [80]. Notch signaling is crucial for the in vivo maintenance of self-renewing stem cells in varieties of lineages such as neural, but also hematopoietic or mammary [81-83]. Similar to Notch-RBPJk, Stat3 trans-activates GFAP and induces normal neural precursor cells to differentiate into astrocytes in association with HES1, HES5 or HEY1. At the molecular level, HES1 physically interacts with Jak2 and Stat3 to induce Stat3 phosphorylation and relevant activation [25,35,84]. Conversely, the association between Notch, RBPJk and β-catenin maintains the precursor cell status [26].

Notch2 and HES1 have been shown to maintain the granule neuron progenitor cell population and inhibit further neuronal differentiation [23]. Reciprocally, brain-derived EGFL7 regulates Notch-dependent proliferation and differentiation of NSC of the subventricular zone into neurons and oligodendrocytes [28]. Further, neuron-induced Jag1-Notch1 signaling upregulates expression of the radial glia marker brain lipid binding protein (BLBP) [68]. In addition, the gene for Nestin, a marker for neural precursors, is trans-activated by Notch signaling [85]. Consistently, in ependymoma cells, the fraction of CD133-positive cells shows significant coexpression of Notch2 and HES1 [72]. This supports a function of Notch signaling in maintaining the GSC population within a tumor. However, Notch signaling has also been shown to trans-activate the gene for GFAP [86] and to drive the differentiation of glial progenitor cells into astrocytes therefore preventing differentiation into oligodendrocytes [87]. This is consistent with the observation that Notch1 and Notch2 are present at high levels in GBM and astrocytoma [55]. These distinct activities suggest multiple roles for Notch signaling in the course of gliomagenesis, in particular in GBM and astrocytoma development, that remain to be dissected. In oligodendrogliomas, Notch2 is frequently deleted and the corresponding protein is not detectable [54,55].

MicroRNAs (miRNAs) are short single-stranded RNAs that negatively regulate gene activity by targeting mRNAs for cleavage or translational repression [88]. The miRNA miR-199b-5p has been recently identified as a regulator of the Notch pathway by targeting the transcription factor HES1. Its overexpression blocks expression of several CSC genes and decreases the medulloblastoma stem-cell-like (CD133+) subpopulation of cells [89]. Similarly, treatment of ependymoma neurospheres with GSI-IX results in decrease sphere number, size, proliferation and induced cell-surface adhesion [76]. GSI have been proved to significantly reduce radio-resistance of glioma stem cells through inhibition of Notch [90].

GSCs represent a critical therapeutic target to control glioma growth and progression. However, the molecular mechanisms that regulate the stem cell pool are poorly understood. The vascular, perinecrotic and hypoxic niches of the tumor constitute a microenvironment that contributes to the regulation of CSC. Hypoxia plays a key role in the regulation of the CSC phenotype through hypoxia inducible factor (HIF)-2α and subsequent induction of specific CSC signature genes, including mastermind-like protein 3 (Notch pathway), nuclear factor of activated T cells 2 (calcineurin pathway) and aspartate β-hydroxylase domain-containing protein 2 [91].

MicroRNA-34a (miR-34a) is a transcriptional target of TP53 that is downregulated in GBM and even more in GBM carrying a TP53 mutation, as compared to normal brain. Transient expression of miR-34a in GBM cells strongly inhibited glioma xenograft growth in vivo by targeting c-Met and Notch [92].

Hypoxia and angiogenesis

GBM possesses a chaotic tumor structure consisting of accumulating tumors cells, abnormal vessel and necrotic debris. The increasing tumor mass leads to pressure gradient leading to capillary and venous collapse [66]. The new formed vessels are structurally and functionally abnormal, and leaky, giving rise to edema, high interstitial fluid pressure and, consecutively, low oxygen tension [93]. In contrast to high O2 tension, which degrades HIF-1α (hypoxia inducible factor) and promotes
Notch signaling and Notch inhibitors can be crucial for the therapeutic benefit in brain tumors. The Notch pathway plays a critical role in the regulation of cell proliferation, apoptosis, and differentiation. In gliomas, Notch signaling can be activated by various tumor microenvironment factors, such as hypoxia-inducible factor-1 (HIF-1) and transforming growth factor beta (TGF-β). These factors can upregulate Notch ligands and receptors, leading to Notch activation and downstream effector gene expression.

**Manipulating the Notch network in brain tumors for therapeutic benefit**

Manipulating the Notch pathway would directly and indirectly influence all the downstream and collateral pathways that interact with the complex Notch family signaling. The Notch signaling target genes, including trans-activated genes and upregulated genes in gliomas, can be regulated by Notch signaling through transcription factors such as HES1, HEY1, BLBP, and NESTIN. Manipulating the Notch network in brain tumors for therapeutic benefit poses as sharper therapeutic agents devoid of side effects against various tumor types in mouse xenograft models [107,110]. The use of mouse glioma models put into specific Notch mutant backgrounds may help to solve this issue. Further downstream, the role of non-canonical Notch pathway has not been clarified yet and more in-depth studies will be needed to define the effect on Notch canonical pathway.

**Concluding remarks and discussion**

GBM is the most prevalent and the most aggressive brain tumor against which conventional therapies, that is, radiotherapy, chemotherapy and surgery have led until now to only transient clinical response followed by tumor recurrence, with no significant improvement of patient survival. Notch signaling has recently been identified to cumulate oncogenic activities in GBM proliferation, apoptosis inhibition and invasion. Additional functions in maintaining non-neoplastic neural stem cells and in neovascularization and in EMT switch of functions in maintaining non-neoplastic neural stem cells and in GBM modulation of proliferation, angiogenesis, invasion and cancer stem cell maintenance suggests by default that both are mostly redundant. Indeed, the pharmacological approaches using GSI do not discriminate for a specific Notch receptor and cause gastrointestinal toxicity as side effect [106]. However, based on the specific role of Dll4-Notch1 in neovascularization, anti-Dll4, and similarly anti-Notch1 and anti-Notch2 antibodies have been proposed as sharper therapeutic agents devoid of side effects against various tumor types in mouse xenograft models [107,110]. The use of mouse glioma models put into specific Notch mutant backgrounds may help to solve this issue. Further downstream, the role of non-canonical Notch pathway has not been clarified yet and more in-depth studies will be needed to define the effect on Notch canonical pathway.

**Clinical studies using Notch inhibitors**

Notch signaling has emerged as a specific therapeutic target for T-ALL [50] and colon cancer [106], as well as a potential target against tumor angiogenesis [105,107,108]. Blocking of Notch pathway induces apoptosis and depletes cancer stem cells in medulloblastoma [109]. A phase I study of GSI MK0752 for adult and pediatric patients with relapsed or refractory acute t-cell lymphoblastic leukemia and lymphoma is ongoing (NCT00100152). More recently, a phase I study of MK0752 was initiated in patients with metastatic or locally advanced breast cancer and other solid tumors (NCT00106145). A new clinical trial has just started for treating patients with recurrent or progressive GBM using GSI RO4929097 (NCT01122901) http://clinicaltrials.gov/ct2/show/NCT01122901?term=notch&rank=14.

Notch signaling has recently been identified to cumulate oncogenic activities in GBM proliferation, apoptosis inhibition and invasion. Additional functions in maintaining non-neoplastic neural stem cells and in neovascularization and in EMT switch of functions in maintaining non-neoplastic neural stem cells and in GBM modulation of proliferation, angiogenesis, invasion and cancer stem cell maintenance suggests by default that both are mostly redundant. Indeed, the pharmacological approaches using GSI do not discriminate for a specific Notch receptor and cause gastrointestinal toxicity as side effect [106]. However, based on the specific role of Dll4-Notch1 in neovascularization, anti-Dll4, and similarly anti-Notch1 and anti-Notch2 antibodies have been proposed as sharper therapeutic agents devoid of side effects against various tumor types in mouse xenograft models [107,110]. The use of mouse glioma models put into specific Notch mutant backgrounds may help to solve this issue. Further downstream, the role of non-canonical Notch pathway has not been clarified yet and more in-depth studies will be needed to define the effect on Notch canonical pathway.

**Prerequisites need to be fulfilled by a compound potentially designed for targeted GBM therapy. The drug needs to be harmless for healthy cells and to be able to pass the blood brain barrier to penetrate the tumor. Further, as previously shown in vitro [111,112], combinations of compounds that target non-redundant GBM pathways or with cytotoxic agents may synergize to induce GBM cell death. Such combinations that would include Notch signaling inhibitors are hoped will provide promising therapies to substantially improve patient outcomes.**
Acknowledgements
This work was supported by Oncosuisse (01338; OCS-01613-12-2004), Regional Cancer League of Basel-Stadt and Baselland (No. 7-2004)

Author details
1 Laboratory of Molecular Neuro-Oncology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland. 2 Laboratory of Brain Tumor Biology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.

Authors’ contributions
ML and JL Boulay assisted in the review conceptualization, design and writing of the manuscript. AM assisted with the review and writing of the manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 12 July 2010 Accepted: 15 November 2010
Published: 15 November 2010

References
1. Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2002, 2616-626.
2. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglioma gliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
3. Newton HB. The molecular and genetic basis of neurological differentiation of neural precursor cells. Science 2001, 291:167-181.
4. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. The Notch pathway molecules are Notch signaling: cell fate control by maintaining proliferation. Neurooncology 2001, 3:15-36.
5. Mitsiades T, Quinn AM, Carcanciu ML, Ordentlich P, Heitler P, Zaidi D. The novel Notch homologue mouse Notch1, Notch2, and Notch3 suggest multiple functional roles of the Notch-DLL signaling system during brain development. J Comp Neurol 2001, 436:167-181.
6. Weinmaster G, Roberts VJ, Lemke G. Notch2: a second mammalian Notch gene. Development (Cambridge, England) 1998, 116:931-941.
39. Garg V, Muth AN, Ransford JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437:270-274.

40. McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Kvaard H, Piccoli DA, Spinner NB. NOTCH2 mutations cause Aalgliese syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 2009, 76:169-173.

41. Jouet A, Corpechot C, Ducros A, Vahedi K, Chabrit H, Mouton P, Alamowitch S, Dommenga V, Cecillon M, Marechal E, Maciaiez J, Vayssiere C, Cruaud C, Cabanas EA, Routtout MM, Weissenbach J, Bier JS, Bousquet MG, Toumier-Lasserve E. NOTCH3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996, 383:707-710.

42. Wei J. Hemmings GP. The NOTCH4 locus is associated with susceptibility to schizophrenia. Nat Genet 2005, 37:36-37.

43. Limbourg FP, Tankshe K, Radlke F, Bronson RT, Chin MT, Liao JK. Essential role of endothelial NOTCH1 in angiogenesis. Circulation 2005, 111:1826-1832.

44. Takeshita K, Satoh M, Ii M, Silverman LB, Sanchez-Irizarry C, Bray SJ.

45. Limbourg FP, Takeshita K, Radlke F, Bronson RT, Chin MT, Liao JK. Essential role of endothelial NOTCH1 in angiogenesis. Circulation 2005, 111:1826-1832.

46. Gallo NW, Dominguez MG, Nogueras J, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G, Yancopoulos GD. Haplosufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A 2004, 101:15949-15954.

47. Bray SJ. Notch signaling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006, 7:679-689.

48. Ellison LW, Bird J, West DC, Sorensen AL, Reynolds TC, Smith SD, Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66:649-661.

49. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC. Activating mutations of NOTCH1 in human T-cell acute lymphoblastic leukemia. Science 2004, 306:269-271.

50. Lee SY, Kumano K, Nakazaki K, Sanada M, Matsumoto A, Yamamoto G, Nannya Y, Suzuki R, Ota S, Ota Y, Iwatsuki K, Sakata-Yanagimoto M, Hangaiashi A, Yagita H, Fukayama M, Seto M, Kurokawa M, Ogawa S, Chiba S. Gain-of-function mutations and copy number increases of NOTCH1 in diffuse large B-cell lymphoma. Cancer Sci 2009, 100:920-926.

51. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumor suppressor? Nat Rev Cancer 2003, 3:756-767.

52. Guentchev M, McKay RD. Notch signaling regulates radial glia differentiation through multiple transcriptional mechanisms. J Neurosci 2006, 26:3102-3108.

53. Fan KW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA. EGFR signals to mTOR through PKC and independently of Akt in glioma. EMBO J 2004, 23:1155-1165.

54. Garcia-Castro A, Faisser A, Kocjan C. Knockout mice reveal a contribution of the extracellular matrix molecule tenasin-C to neural precursor proliferation and migration. Development (Cambridge, England) 2001, 128:2483-2495.

55. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005, 9:617-628.

56. Nishio T, Kawaguchi S, Yamamoto M, Kedda T, Kawasaki T, Hase T. Tenasin-C regulates proliferation and migration of cultured astrocytes in a scratch wound assay. Neuroscience 2005, 132:87-102.

57. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenasin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 2003, 98:2430-2439.

58. Pugari S, Girll J, Valant A, Bieche I, Dantas-Barbosa C, Kaufmann A, Dessen P, Lacroix L, Geigerer B, Job B, Devirne C, Varlet P, Peyre M, Dirks PB, Sainte-Rose C, Vassal G. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol 2009, 27:1884-1892.

59. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells in cancer, and cancer stem cells. Nature 2001, 414:105-111.

60. Alles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007, 18:460-466.
80. Voog J, Jones DL: Stem cells and the niche: a dynamic duo. Cell Stem Cell 6:103-115.
81. Duncan AW, Ratts FM, DiMascio LN, Congdon RL, Pazzanos G, Zhao C, Yoon K, Cook JM, Willert K, Gaona N, Hey I: Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 2005, 6:134-322.
82. Kageyama R, Ohtsuka T, Hatakeyama J, Ohshara R: Roles of bHLH genes in neural stem cell differentiation. Exp Cell Res 2005, 306:343-348.
83. Woodward WA, Chen MS, Behbood F, Rosen JM: On mammalian stem cells. J Cell Sci 2005, 118:3585-3594.
84. Fischer A, Gessler M: Delta-Notch--and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 2007, 35:4583-4596.
85. Shih AH, Holland EC: Notch signaling enhances nestin expression in gliomas. Neoplasia 2006, 8:1072-1082.
86. Ge W, Martinovich K, Wu X, He F, Miyanoto A, Fan G, Weisgamer M, Sun Y, Ye: Notch signaling promotes astroglial differentiation via direct CSL-mediated giall gene activation. J Neurosci Res 2002, 69:848-860.
87. Wu Y, Liu Y, Levine EM, Rao MS: Hes1 but not Hes5 regulates an astrocyte versus oligodendrocyte fate choice in glial restricted precursors. Dev Dyn 2003, 226:675-689.
88. Bertal DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
89. Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navis G, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Vecchio LD, Northcott PA, Delatre O, Taylor MD, Iolascon A, Zollo M: MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS ONE 2009, 4:e4998.
90. Wang H, Latha JO, Wu Q, Wang J, Li Z, Hedderston JM, Syler CE, Elderbroon I, Gallagher J, Schachter J, Mackward J, Cao Y, McLendon RE, Wang XF, Hjelmeland AB, Rich JH: Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009, 27:2393-2404.
91. Sedel S, Ganavolak BK, Wirta V, von Stechow L, Schanzer A, Meletis K, Wolter M, Sonmez O, Deniz S, Fink DJ, Reifenberger G, Dandlberg J, Frisen J, Acker T: A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2a. Brain 133:983-995.
92. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, Purov B, Abounader R: microRNA-34a is tumor suppressive in glioblastoma precursors. BMC Medicine 2010, 10:2.
93. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K: Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMGB box factors. Cell Stem Cell 2009, 5:504-514.
94. Bruna A, Darken RS, Roca F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J, High TGF-beta Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007, 11:147-160.
95. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thorson G: Blockade of Dll4 inhibits tumor growth by promoting non-productive angiogenesis. Nature 2006, 444:1032-1037.
96. van Es JH, van Ginneken MJ, Groenendijk M, Plettenberg A, van Gijn ME, Riccio O, van den Born M, Vooijj M, Bregthel H, Cozijn M, Robine S, Winton DJ, Radtke F, Clevers H: Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 433:959-963.
97. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chandhry Y, Kowalski J, Watts RJ, Callahan C, Kasman L, Singh M, Chen M, Tan C, Hong JA: Dll4 inhibition of Notch signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
98. Kappan R, Ilaan MX: The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-223.
99. Fan X, Matsu W, Khaki L, Stearns D, Chou J, Li YM, Eberhart CG: Notch pathway inhibition depletes stem-like cells and blocks engrafment in embryonal brain tumors. Cancer Res 2006, 66:7445-7452.
100. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Landenson PW, Sidransky D, Xing M: Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 2005, 90:4688-4693.
101. Fially M, Konur S, Egler V, Boulay JL, Lino MM, Imber R, Merlo A: Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Mol Cancer Ther 2007, 6:773-781.
102. Egler V, Konur S, Fially M, Boulay JL, Imber R, Lino MM, Merlo A: Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin Cancer Res 2008, 14:3132-3140.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1741-7015/8/72/prepub

doi:10.1186/1741-7015-8-72
Cite this article as: Lino et al: Notch signaling in glioblastoma: a developmental drug target?. BMC Medicine 2010:8.72.